Biotech & Pharma

Our Biotech & Pharma Expertise

Whether you’re a pre-clinical drug discovery startup, a CRO, CDMO, or a company in the pharma supply chain, building and managing your reputation is critical. 

For many companies involved in drug development, clinical trials and pharmaceutical manufacturing, investing in public relations is not a priority.

But it is important, because operating in a regulated, complex, reputation-driven sector requires professional communications, delivered by competent experts.

Our expertise in life sciences is the reason we represent some of the most dynamic biotech and pharmaceutical clients, from Nevrargenics developing small molecule drugs for neurodegeneration, to Healome developing ocular therapeutics.

What our clients are looking for and why they choose us 

Many of our startup clients are looking to raise their profile with investors and work directly with industry with a view to securing a licensing agreement or having their IP acquired. Whilst larger clients are looking to position themselves and their company as thought leaders and to raise their industry profile to enhance business development activity. 

Expertise manifests itself in different ways. For us, it is expressed through a combination of deep understanding of the drug development and commercialisation process; honed intuition on how to develop media angles and communicate distinctively; and long term relationships we have formed with the most influential biotech and pharma journalists.

Clients see us as advisors. They draw on our knowledge to help them make better strategic decisions, and our skills to raise their profile and influence key stakeholders.

  • Strategy

    Strategy workshops and away days

    Reputation audits

    Communications strategy development

  • PR

    Media mapping and monitoring

    Press and media liaison

    Story and narrative development

    Events and launches

    Investor pitch decks

  • Public affairs

    Stakeholder mapping

    Legislative monitoring

    Parliamentary and ministerial engagement

    Crisis communications and issues management

  • Specialist content

    Thought leadership

    White papers

    Product literature and brochures

    KOLs and blog content

    Case studies

  • Investor relations

    Investor PR

    Pitch decks

    Executive profiling

    Go-to-market strategy

    Event support

  • Digital advertising

    Digital audits

    Digital marketing strategy

    Google PPC

    LinkedIn advertising

CROs, CMOs and CDMOs

CROs and CDMOs often rely on referrals for new business development. 

This presents a huge opportunity for those who invest in public relations and building a brand.

By working with us to raise your profile within the early stage drug discovery and biotech sector, CROs, CMOs and CDMOs can increase awareness, strengthen positioning and improve recall amongst target audiences. This is a proven way of increasing sales pipelines and enhancing customer retention.

Clients choose us for our expertise and ability. We work with pharma and biotech clients to place news stories, thought leaders and specialist features in the pharma, biotech and drug development media.

Drug discovery & development

The focus for most of our early stage biotech clients is raising investment and securing licensing agreements with larger pharmaceutical firms.

We work with clients to increase their profile with angel, VC and PE investors and build a strong media presence that helps to attract, influence and persuade investors looking to make seed to Series A investments. 

Our relationships with biotech media outlets, and our specialist sector knowledge, enables us to secure valuable thought leadership opportunities for clients to demonstrate their expertise. This has included securing articles on everything from the use of animal models in neurodegeneration to the use of neurofilament light analysis as an effective biomarker technique.

Our point of difference

Most agencies can’t do biotech or pharma communications properly because they don’t understand how technology scouts and R&D leads make decisions, how medicines are developed or how to map clinical trial milestones onto media opportunities to build interest amongst investors.

We do, and apply our knowledge of bench to Phase III to provide clients with added value above that helps them to win new business, raise investment and establish industry partnerships.

Our track record speaks for itself - from helping clients to effectively communicate a value proposition distinctively to attracting inbound industry partnership interest, life sciences leaders appoint Tarleton because of our expertise and ability.

Some of the coverage we have secured